Self-assessment Q&A in Clinical Laboratory Science, III, adds a variety of subject matter that addresses new concepts and emerging technology, particularly in the areas of kidney biomarkers, cancer biomarkers, molecular diagnostics, multiple myeloma, pharmacogenomics, novel cardiovascular biomarkers and biomarkers of neurologic diseases. The field of Clinical Laboratory Science continues to evolve and editor Alan Wu has once again brought together experts in the field to cover the contemporary topics that are being tested today. This updated bank of questions and answers is a must-have to sharpen knowledge and skills.

While the basic principles of personalized medicine and pharmacogenomics have been covered by numerous texts, there are none to date that focus on the specific tests themselves that are in current clinical practice and those that are being proposed for implementation in the near future. Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory focuses almost entirely on the specifics of each test that is needed to implement these tests into a clinical laboratory. This volume presents the first compilation of the tests currently in routine clinical use. The chapter authors of this unique and invaluable title comprise a range of renowned authorities and investigators who have conducted the essential clinical trials necessary to justify pharmacogenomic testing today. The book is divided into four parts: Basic Concepts, Specific Pharmacogenomic Targets, Drugs that Cause Delayed Hypersensitivity, and Miscellaneous Drugs. Each author provides a pharmacologic background on the target drug, the need for pharmacogenomic testing, and how results can be translated into clinical decisions. Where appropriate, case studies are given to illustrate typical clinical scenarios. An extensive bibliography is provided so that the reader can refer to the original studies. This well-designed resource will appeal to clinical laboratory directors who are contemplating or assigned the task of establishing a pharmacogenomics laboratory and a wide range of clinicians who must interpret results of testing. Focused and immensely useful, Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory is a timely and outstanding contribution to the literature and will be instrumental in defining this rapidly growing field.

In this greatly enlarged and thoroughly updated edition of his much praised Cardiac Markers, Alan Wu and his contributors focus on the use of markers in the practice of cardiology and-for the first time-on the use of natriuretic peptides for congestive heart failure. Here, leading international authorities in clinical chemistry and laboratory medicine, cardiology, emergency medicine, and the in vitro diagnostics industry describe the state-of-the-art uses of cardiac markers when treating coronary artery disease, and discuss in detail how they may be optimally used in a clinical setting. Comprehensive and cutting-edge, Cardiac Markers, Second Edition offers physicians a complete guide to the use of cardiac markers in clinical practice and clinical laboratorians a close-up view of the new markers now becoming standard.

Cardiac Markers is a comprehensive, up-to-date summary of clinical information on serum cardiac markers for coronary artery disease. This book reviews in detail the biochemistry, clinical significance, and analytical measurements for each marker, as well as the advantages and limitations of existing and proposed markers. Comprehensive descriptions of therapeutic approaches to manage patients are presented. Also included are up-to-date listings of primary references and commercial methodologies, the latest data on the pathophysiology of unstable angina, and a discussion of the new emergency-room chest pain centers. Anyone who needs to know how to examine, diagnose, treat, and manage patients with acute chest pain and heart attacks will find this book indispensable.

Biomarkers for Traumatic Brain Injury provides a comprehensive overview on the selection and implementation of serum-based and saliva-based biomarkers for traumatic brain injury. The book presents an economic analysis for implementing TBI biomarkers into clinical practice. In addition, it discusses the analytical tools needed to implement TBI biomarkers, including specifications for testing instruments and interpretative software. Neurologists, emergency department physicians, intensivists, and clinical laboratorians will find this book a great resource from which to familiarize themselves with the issues and processes regarding TBI biomarkers. Approximately 2 million people in the U.S. sustain a traumatic brain injury (TBI) each year with over 250,000 hospitalizations and 50,000 deaths. There has been a significant rise in interest in diagnosing mild concussions, particularly in the sports world. While imaging has been the gold standard, these procedures are costly and not always available. There is great potential in using serum-based biomarkers, hence the book seeks to enlighten readers on new possibilities.

While the basic principles of personalized medicine and pharmacogenomics has been covered by numerous texts, there are none to date that focuses on the specific tests themselves that are in current clinical practice and those that are being proposed for implementation in the near future. Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory focuses almost entirely on the specifics of each test that is needed to implement these tests into a clinical laboratory. This volume presents the first compilation of the tests currently in routine clinical use. The chapter authors of this unique and invaluable title comprise a range of renowned authorities and investigators who have conducted the essential clinical trials necessary to justify pharmacogenomic testing today. The book is divided into four parts: Basic Concepts, Specific Pharmacogenomic Targets, Drugs that Cause Delayed Hypersensitivity, and Miscellaneous Drugs. Each author provides a pharmacologic background on the target drug, the need for pharmacogenomic testing, and how results can be translated into clinical decisions. Where appropriate, case studies are given to illustrate typical clinical scenarios. An extensive bibliography is provided so that the reader can refer to the original studies. This well-designed resource will appeal to clinical laboratory directors who are contemplating or assigned the task of establishing a pharmacogenomics laboratory and a wide range of clinicians who must interpret results of testing. Focused and immensely useful, Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory is a timely and outstanding contribution to the literature and will be instrumental in defining this rapidly growing field.

Cardiac Markers is a comprehensive, up-to-date summary of clinical information on serum cardiac markers for coronary artery disease. This book reviews in detail the biochemistry, clinical significance, and analytical measurements for each marker, as well as the advantages and limitations of existing and proposed markers. Comprehensive descriptions of therapeutic approaches to manage patients are presented. Also included are up-to-date listings of primary references and commercial methodologies, the latest data on the pathophysiology of unstable angina, and a discussion of the new emergency-room chest pain centers. Anyone who needs to know how to examine, diagnose, treat, and manage patients with acute chest pain and heart attacks will find this book indispensable.

In this greatly enlarged and thoroughly updated edition of his much praised Cardiac Markers, Alan Wu and his contributors focus on the use of markers in the practice of cardiology and-for the first time-on the use of natriuretic peptides for congestive heart failure. Here, leading international authorities in clinical chemistry and laboratory medicine, cardiology, emergency medicine, and the in vitro diagnostics industry describe the state-of-the-art uses of cardiac markers when treating coronary artery disease, and discuss in detail how they may be optimally used in a clinical setting. Comprehensive and cutting-edge, Cardiac Markers, Second Edition offers physicians a complete guide to the use of cardiac markers in clinical practice and clinical laboratorians a close-up view of the new markers now becoming standard.

Toxicology Because what you don't know can kill you is about everyday people and their encounters with the clinical laboratory. This collection of stories is a behind-the-scenes look at the intricate workings of a toxicology lab. Many of these cases ended with legal consequences. All stories are based on my involvement with real cases as a toxicologist. Because of patient privacy laws, the names and places have been changed. We all wish we had more power. The power to turn back time, to re-write history and make better decisions, but most importantly, the power to save a life. However, the dream of being someone's hero or even saving yourself from certain death or misfortune is a plight that no average person can seemingly muster. Without super strength or extrasensory perceptions, it may appear that we are on our own to battle uncertain destiny. But what if I were to tell you there's more? There's a way to change your fate, to hold more cards, and take not only your own life, but the lives of those you love into your hands. No, we cannot go back in time, but we can set forth ripples of change into the future that can alter our coexistence forever. Toxicology and clinical laboratory testing may be one of those portals.